Entera Bio is a pre-revenue biotech dependent on its EB613 program, with quarterly losses of about 0.06 to 0.14 per share and an uptrend pullback on strong volume, but quality sits below the engine's floor.
Thesis pillars
- Single Program Concentration↓Deteriorating
- Cash Burning Pre Revenue→Stable
- Uptrend Pullback Volume↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Oct 11, 2026, based on the 10-K filed Mar 27, 2026
Entera Bio Ltd. (ENTX) Stock Analysis
Momentum Cont setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.10: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: Below-average business quality.
Entera Bio Ltd. is a clinical-stage company developing oral tablet peptide and protein replacement therapies via its N-Tab platform, led by EB613 for osteoporosis and EB612 for hypoparathyroidism, plus GLP-1/Glucagon and GLP-2 programs partnered with OPKO Biologics. The company... Read more
Sell if holding. Engine safety override at $3.10: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: Below-average business quality. Chart setup: Trend continuation, RSI 70, MACD bullish. Score 4.3/10, moderate confidence.
Passes 4/7 gates (clean insider activity, earnings proximity 15d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Entera Bio Ltd.
About Entera Bio Ltd.
Entera Bio's clinical pipeline centers on EB613, an oral once-daily PTH(1-34) tablet for postmenopausal osteoporosis advancing toward a roughly 750-patient Phase 3 study after the FDA's December 2025 qualification of total hip bone mineral density as a surrogate fracture endpoint. The company also develops EB612 for hypoparathyroidism and, with OPKO Biologics, oral GLP-1/Glucagon (EB618) and GLP-2 programs, while reporting no product revenue, an $11.4 million 2025 net loss, and a $125.4 million accumulated deficit.
Entera generates no product revenue today; its business model instead rests on advancing its N-Tab oral-delivery platform, designed to stabilize large hydrophilic peptides against gastrointestinal enzymatic degradation and promote their absorption into the bloodstream, and monetizing that platform through wholly owned and partnered pipeline assets. Entera retains global rights to EB613, its lead osteoporosis candidate, while its hypoparathyroidism, oral GLP-1/Glucagon, and GLP-2 programs run through collaboration and license agreements with OPKO Biologics: the companies split EB612 rights 50/50, and Entera and OPKO split OXM (EB618) proceeds and development costs 40/60, respectively, falling to a 15/85 split if Entera exercises its post-Phase-1 opt-out. The FDA has granted EB612 orphan drug designation, and Entera's most advanced clinical dataset — a Phase 2, 6-month, 161-patient placebo-controlled trial of EB613 — met all biomarker and bone-density endpoints, with results published in the Journal of Bone and Mineral Research in April 2024.
Show full overview
EB613 functions as a binary bet for Entera: the 10-K states existing cash would fund operations only through the middle of the third quarter of 2026, explicitly excluding the costs of starting the Phase 3 osteoporosis trial, and management flagged substantial doubt about the company's ability to continue as a going concern. In July 2026, the company disclosed via Form 8-K a $275.0 million private placement priced at $2.04 per share, addressing that funding gap; because EB613 is Entera's most advanced program and the one to which it retains full global rights (unlike EB612, EB618, and GLP-2, which are shared with OPKO), any delay in Phase 3 execution or an unfavorable readout would disproportionately weigh on the company relative to its partnered assets.
See also: Healthcare · Biotechnology
From Entera Bio Ltd.'s most recent 10-K filing, extracted August 30, 2026.
Recent developments
updated 2026-10-29Recent Developments — Entera Bio Ltd.
Latest news
- NEWS Entera Bio Appoints Dr. Juan Camilo Arjona Ferreira to Board of Directors — fiscal.ai Oct 27, 2026 neutral
- NEWS Entera Bio Presents Phase 2 Data Supporting EB613 Benefits In Women With Osteoporosis At ASBMR 2026 Annual Meeting — benzinga Oct 13, 2026 positive
- NEWS 12 Health Care Stocks Moving In Friday's Pre-Market Session — benzinga Oct 9, 2026 neutral
- NEWS Alignment Healthcare, RenX Enterprises And Other Big Stocks Moving Lower In Friday’s Pre-Market Session — benzinga Oct 9, 2026 neutral
- NEWS Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11 — benzinga Sep 25, 2026 positive
Generated 2026-10-29T11:53:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineEB61310-K Item 1A: 'our internal resources are currently focused on the development of EB613 and further development of our N-Tab® platform'
Material Events(8-K, last 90d)
- 2026-07-28Item 1.01HIGHOn July 26, 2026, Entera entered a Securities Purchase Agreement for a $275.0 million private placement of ordinary shares and pre-funded warrants to institutional investors including BVF Partners, priced at $2.04/share; closed July 28, 2026, addressing the company's previously disclosed going-concern funding gap.SEC filing →
- 2026-07-16Item 5.02LOWAt its Annual Meeting, shareholders approved an amendment to Entera's 2018 Equity Incentive Plan increasing the share pool by a one-time 2,500,000 ordinary shares; a routine plan amendment, not an executive departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.10: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: Below-average business quality. Chart setup: Trend continuation, RSI 70, MACD bullish. Prior stop was $2.88. Score 4.3/10, moderate confidence.
Resistance target: $3.19 (+2.9% upside). Prior stop was $2.88. Stop-loss: $2.88.
Concentration risk — Pipeline: EB613; DATA_ISSUE: analyst_target_implausible (raw $9.75 vs price $3.10 — ratio 3.1×). Rejected, falling back to technical TP.; Quality below floor (1.6 < 4.0).
Entera Bio Ltd. trades at a P/E of N/A (forward -5.6). TrendMatrix value score: 5.0/10. Verdict: Sell.
11 analysts cover ENTX with a consensus score of 4.3/5. Average price target: $10.
What does Entera Bio Ltd. do?Entera Bio Ltd. is a clinical-stage company developing oral tablet peptide and protein replacement therapies via its...
Entera Bio Ltd. is a clinical-stage company developing oral tablet peptide and protein replacement therapies via its N-Tab platform, led by EB613 for osteoporosis and EB612 for hypoparathyroidism, plus GLP-1/Glucagon and GLP-2 programs partnered with OPKO Biologics. The company has no product revenue, posted an $11.4 million net loss in 2025 on a $125.4 million accumulated deficit, and faces substantial doubt about its ability to continue as a going concern.